nach oben

Pharmaceutical Medicine

Erschienen in:

01.06.2011 | Update

Journal Watch

Erschienen in: Pharmaceutical Medicine | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Excerpt

1. Personalized Medicine —Trends in Molecular Diagnostics: Exponential Growth Expected in the Next Ten Years
2. Transdermal Patch Drug Delivery Interactions with Exercise
3. Strategies for Quantifying the Relationship between Medications and Suicidal Behaviour: What has been Learned?
4. The New Seventh Edition American Joint Committee on Cancer Staging of Cutaneous Non-Melanoma Skin Cancer: A Critical Review
5. Modelling the Epidemiology of Infectious Diseases for Decision Analysis: A Primer
6. Sample Size and Power for Cost-Effectiveness Analysis (Part 2): The Effect of Maximum Willingness to Pay
7. The Impact of Inclusion Criteria in Health Economic Assessments
8. Today’s Challenges in Pharmacovigilance: What can we Learn from Epoetins?
9. Strengthening and Rationalizing Pharmacovigilance in the EU: Where is Europe Heading to?: A Review of the New EU Legislation on Pharmacovigilance
10. Sensitivity Analysis in Cost-Effectiveness Studies: From Guidelines to Practice
11. Antiretroviral Drugs in Pediatric HIV-Infected Patients: Pharmacokinetic and Practical Challenges
12. Current Status and Future Directions of Gene and Cell Therapy for Cystic Fibrosis
13. Individual Case Safety Reports —How to Determine the Onset Date of an Adverse Reaction: A Survey
14. Mortality Rates and Causes of Death in Children with Epilepsy Prescribed Antiepileptic Drugs: A Retrospective Cohort Study using the UK General Practice Research Database
15. Suspected Adverse Drug Reactions Reported For Children Worldwide: An Exploratory Study Using VigiBase
16. How Patient Reporters Identify Adverse Drug Reactions: A Qualitative Study of Reporting via the UK Yellow Card Scheme
17. The Impact in Japan of Regulatory Action on Prescribing of Dopamine Receptor Agonists: Analysis of a Claims Database between 2005 and 2008
18. Towards a Better Prediction of Peak Concentration, Volume of Distribution and Half-Life after Oral Drug Administration in Man, Using Allometry
19. Simulation of Human Intravenous and Oral Pharmacokinetics of 21 Diverse Compounds Using Physiologically Based Pharmacokinetic Modelling
20. Limited Capacity in US Pediatric Drug Trials: Qualitative Analysis of Expert Interviews
21. Recombinant Drug Development, Regulation, and Commercialization: An Indian Industry Perspective
22. Assessing the Performance of a New Generic Measure of Health-Related Quality of Life for Children and Refining it for Use in Health State Valuation

…

Hoggatt J. Personalized medicine — trends in molecular diagnostics: exponential growth expected in the next ten years. Mol Diagn Ther 2011; 15 (1): 53–5PubMedCrossRef

Lenz TL, Gillespie N. Transdermal patch drug delivery interactions with exercise. Sports Med 2011; 41 (3): 177–83PubMedCrossRef

Gibbons RD, Mann JJ. Strategies for quantifying the relationship between medications and suicidal behaviour: what has been learned? Drug Saf 2011 34 (5): 375–95PubMedCrossRef

Warner CL, Cockerell CJ. The new seventh edition American Joint Committee on Cancer Staging of Cutaneous Non-Melanoma Skin Cancer: a critical review. Am J Clin Dermatol 2011; 12 (3): 147–54PubMedCrossRef

Jit M, Brisson M. Modelling the epidemiology of infectious diseases for decision analysis: a primer. Pharmacoeconomics 2011; 29 (5): 371–86PubMedCrossRef

Glick HA. Sample size and power for cost-effectiveness analysis (part 2): the effect of maximum willingness to pay. Pharmacoeconomics 2011; 29 (4): 287–96PubMed

Richter A, Thieda P, Thaler K, et al. The impact of inclusion criteria in health economic assessments. Appl Health Econ Health Pol 2011; 9 (3): 139–48CrossRef

Ebbers HC, Mantel-Teeuwisse AK, Moors EH, et al. Today’s challenges in pharmacovigilance: what can we learn from epoetins? Drug Saf 2011; 34 (4): 273–87PubMedCrossRef

Borg J-J, Aislaitner G, Pirozynski M, et al. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance. Drug Saf 2011; 34 (3): 187–97PubMedCrossRef

Jain R, Grabner M, Onukwugha E. Sensitivity analysis in cost-effectiveness studies: from guidelines to practice. Pharmacoeconomics 2011; 29 (4): 297–314PubMed

Phelps BR, Rakhmanina N. Antiretroviral drugs in pediatric HIV-infected patients: pharmacokinetic and practical challenges. Pediatr Drugs 2011; 13 (3): 175–92CrossRef

Griesenbach U, Alton EW. Current status and future directions of gene and cell therapy for cystic fibrosis. Biodrugs 2011; 25 (2): 77–88PubMedCrossRef

Klepper MJ, Edwards B. Individual case safety reports — how to determine the onset date of an adverse reaction: a survey. Drug Saf 2011; 34 (4): 299–305PubMedCrossRef

Ackers R, Besag FM, Hughes E, et al. Mortality rates and causes of death in children with epilepsy prescribed antiepileptic drugs: a retrospective cohort study using the UK General Practice Research Database. Drug Saf 2011; 34 (5): 403–13PubMedCrossRef

Star K, Norén GN, Nordin K, et al. Suspected adverse drug reactions reported for children worldwide: an exploratory study using VigiBase. Drug Saf 2011; 34 (5): 415–28CrossRef

Krska J, Anderson C, Murphy E, et al. How patient reporters identify adverse drug reactions: a qualitative study of reporting via theUKYellow Card scheme. Drug Saf 2011; 34 (5): 429–36PubMedCrossRef

Ooba N, Yamaguchi T, Kubota K. The impact in Japan of regulatory action on prescribing of dopamine receptor agonists: analysis of a claims database between 2005 and 2008. Drug Saf 2011; 34 (4): 329–38PubMedCrossRef

Sinha VK, Vaarties K, De Buck SS, et al. Towards a better prediction of peak concentration, volume of distribution and half-life after oral drug administration in man, using allometry. Clin Pharmacokinet 2011; 50 (5): 307–18PubMedCrossRef

Jones HM, Gardner IB, Collard WT, et al. Simulation of human intravenous and oral pharmacokinetics of 21 diverse compounds using physiologically based pharmacokinetic modelling. Clin Pharmacokinet 2011; 50 (5): 331–47PubMedCrossRef

Wasserman R, Bocian A, Harris D, et al. Limited capacity in US pediatric drug trials: qualitative analysis of expert interviews. Pediatr Drugs 2011; 13 (2): 119–24CrossRef

Sahoo N, Manchikanti P. Recombinant drug development, regulation, and commercialization: an Indian industry perspective. Biodrugs 2011; 25 (2): 105–13CrossRef

Stevens K. Assessing the performance of a new generic measure of health-related quality of life for children and refining it for use in health state valuation. Appl Health Econ Health Pol 2011; 9 (3): 157–69CrossRef

Titel: Journal Watch
Publikationsdatum: 01.06.2011
Verlag: Springer International Publishing
Erschienen in: Pharmaceutical Medicine / Ausgabe 3/2011
Print ISSN: 1178-2595
Elektronische ISSN: 1179-1993
DOI: https://doi.org/10.1007/BF03256861

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Journal Watch

Excerpt

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2011

The Role of Health-Related Quality of Life Data in the Drug Approval Processes in the US and Europe

Drugs in Clinical Development for Breast Cancer

Drug and Device Shortages

23rd Annual EuroMeeting of the Drug Information Association

Standardizing the Benefit-Risk Assessment of New Medicines

Forum